English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/50362
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

New druggable targets in the Ras pathway?

AuthorsMatallanas, David; Crespo, Piero CSIC ORCID
KeywordsAntitumor therapy
B-Raf
ERK
Issue Date2010
PublisherThomson Reuters
CitationCurrent Opinion in Molecular Therapeutics 12(6): 674-683 (2010)
AbstractRas proteins are key elements in the regulation of cellular proliferation, differentiation and survival. Mutational activation of Ras or of components of its effector pathways are detected in one-third of human cancers and are essential for the genesis and maintenance of the tumoral phenotype. Research efforts have been dedicated to the development of therapeutic agents that inhibit aberrant Ras signals and, subsequently, tumor progression. However, many of these initiatives have proven less successful than expected. This review summarizes the current status of developments in Ras research, the challenges that have arisen during preclinical and clinical stages, and how novel approaches to targeting Ras pathways have introduced new strategies toward the development of antitumoral agents that are alternative or complementary to those currently in use. These new approaches would be aimed at disrupting key protein-protein interactions that are essential for the conveyance of Ras aberrant signals or would be directed against new proteins recently demonstrated to be critical participants in Ras-regulated pathways.
URIhttp://hdl.handle.net/10261/50362
Identifiersissn: 1464-8431
Appears in Collections:(IBBTEC) Artículos
Files in This Item:
File Description SizeFormat 
New druggable.pdf512,36 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.